<DOC>
	<DOC>NCT00902070</DOC>
	<brief_summary>The main purpose of this investigation is to collect safety and efficacy information of Eslax Intravenous 25mg/2.5mL and 50mg/5.0mL (hereinafter referred to as "Eslax") in daily clinical settings.</brief_summary>
	<brief_title>Protocol for Eslax Intravenous Drug Use Investigation (Study P06082)</brief_title>
	<detailed_description>Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.</detailed_description>
	<mesh_term>Rocuronium</mesh_term>
	<criteria>Patients to whom Eslax has been administered to relax muscles at the time of anesthesia or tracheal intubation. Patients with a history of hypersensitivity to Eslax or bromide. Patients with myasthenia gravis or myasthenic syndrome.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>